Syndax Pharmaceuticals, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Syndax Pharmaceuticals, Inc. (SNDX) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$9.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$1.39M, a 112.90% decline year-over-year.
- Syndax Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$7.84M.
- Syndax Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $5.40M.
- Syndax Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $4.36M, a 59.13% decline year-over-year.
- Syndax Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $14.54M, a 73.26% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $8.39M.
- Syndax Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$676.00K, a 122.75% decline from fiscal 2022.
- Syndax Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $2.97M, a 113.20% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$9.23M 10-Q · filed 2026-08-04 | -$3.83M derived: sum of 3 quarters · filed 2026-08-04 | $538.00K derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | -$7.84M 10-Q · filed 2026-04-30 | -$2.44M derived: sum of 2 quarters · filed 2026-04-30 | $1.93M derived: sum of 3 quarters · filed 2026-04-30 | $12.70M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-12-31 | $5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.76M derived: sum of 2 quarters · filed 2026-02-26 | $20.53M derived: sum of 3 quarters · filed 2026-08-04 | $14.54M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $4.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $15.13M derived: sum of 2 quarters · filed 2026-08-04 | $9.14M 10-Q · filed 2025-11-03 | $5.97M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-06-30 | $10.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $4.78M 10-Q · filed 2026-08-04 | $1.60M derived: sum of 3 quarters · filed 2026-08-04 | $12.28M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | -$5.99M 10-Q · filed 2026-04-30 | -$9.17M derived: sum of 2 quarters · filed 2026-04-30 | $1.51M derived: sum of 3 quarters · filed 2026-04-30 | -$453.00K derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | -$3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.50M derived: sum of 2 quarters · filed 2026-02-26 | $5.54M derived: sum of 3 quarters · filed 2026-02-26 | $8.39M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $10.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $8.71M derived: sum of 2 quarters · filed 2025-11-03 | $11.57M 10-Q · filed 2025-11-03 | $7.61M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | -$1.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $890.00K 10-Q · filed 2025-08-04 | -$3.07M derived: sum of 3 quarters · filed 2026-02-26 | $673.00K derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $2.85M 10-Q · filed 2025-05-05 | -$1.10M derived: sum of 2 quarters · filed 2026-02-26 | $2.64M derived: sum of 3 quarters · filed 2026-02-26 | $5.08M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | -$3.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$217.00K derived: sum of 2 quarters · filed 2026-02-26 | $2.22M derived: sum of 3 quarters · filed 2026-02-26 | -$676.00K 10-K · filed 2026-02-26 | |
| 2023-09-30 | $3.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $6.18M derived: sum of 2 quarters · filed 2024-11-05 | $3.28M 10-Q · filed 2024-11-05 | -$1.42M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | $2.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$459.00K 10-Q · filed 2024-08-01 | -$5.16M derived: sum of 3 quarters · filed 2025-03-03 | -$2.42M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | -$2.90M 10-Q · filed 2024-05-08 | -$7.60M derived: sum of 2 quarters · filed 2025-03-03 | -$4.86M derived: sum of 3 quarters · filed 2025-03-03 | -$8.36M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2022-12-31 | -$4.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$1.96M derived: sum of 2 quarters · filed 2025-03-03 | -$5.46M derived: sum of 3 quarters · filed 2025-03-03 | $2.97M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $2.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$757.00K derived: sum of 2 quarters · filed 2023-11-02 | $7.67M 10-Q · filed 2023-11-02 | $7.60M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | -$3.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $4.93M 10-Q · filed 2023-08-03 | $4.85M derived: sum of 3 quarters · filed 2024-02-27 | $3.97M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $8.43M 10-Q · filed 2023-05-08 | $14.69M 10-Q · filed 2022-05-09 | $8.35M derived: sum of 2 quarters · filed 2024-02-27 | $7.47M derived: sum of 3 quarters · filed 2024-02-27 | $9.16M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$963.00K derived: sum of 2 quarters · filed 2024-02-27 | $734.00K derived: sum of 3 quarters · filed 2024-02-27 | $1.39M 10-K · filed 2024-02-27 | |
| 2021-09-30 | -$886.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $811.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.47M 10-Q · filed 2022-11-03 | -$4.00K derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $2.36M 10-Q · filed 2022-08-08 | $882.00K derived: sum of 3 quarters · filed 2023-02-28 | $4.29M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | $660.00K 10-Q · filed 2022-05-09 | -$815.00K derived: sum of 2 quarters · filed 2023-02-28 | $2.59M derived: sum of 3 quarters · filed 2023-02-28 | $2.44M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | -$1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.93M derived: sum of 2 quarters · filed 2023-02-28 | $1.78M derived: sum of 3 quarters · filed 2023-02-28 | $4.31M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $3.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $3.26M derived: sum of 2 quarters · filed 2021-11-15 | $5.79M 10-Q · filed 2021-11-15 | $5.78M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | -$146.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $2.38M 10-Q · filed 2021-08-09 | $2.37M derived: sum of 3 quarters · filed 2022-03-01 | -$229.00K derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $2.53M 10-Q · filed 2021-05-11 | $2.52M derived: sum of 2 quarters · filed 2022-03-01 | -$83.00K derived: sum of 3 quarters · filed 2022-03-01 | $129.00K derived: sum of 4 quarters · filed 2022-03-01 | |
| 2019-12-31 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$2.61M derived: sum of 2 quarters · filed 2022-03-01 | -$2.40M derived: sum of 3 quarters · filed 2022-03-01 | $52.00K 10-K · filed 2022-03-01 | |
| 2019-09-30 | -$2.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$2.39M derived: sum of 2 quarters · filed 2020-11-05 | $62.00K 10-Q · filed 2020-11-05 | -$3.75M derived: sum of 4 quarters · filed 2021-03-12 | |
| 2019-06-30 | $212.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $2.67M 10-Q · filed 2020-08-06 | -$1.15M derived: sum of 3 quarters · filed 2021-03-12 | -$1.22M derived: sum of 4 quarters · filed 2021-03-12 | |
| 2019-03-31 | $2.45M 10-Q · filed 2020-05-07 | -$1.36M derived: sum of 2 quarters · filed 2021-03-12 | -$1.43M derived: sum of 3 quarters · filed 2021-03-12 | -$1.20M derived: sum of 4 quarters · filed 2021-03-12 | |
| 2018-12-31 | -$3.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$3.88M derived: sum of 2 quarters · filed 2021-03-12 | -$3.65M derived: sum of 3 quarters · filed 2021-03-12 | -$1.03M 10-K · filed 2021-03-12 | |
| 2018-09-30 | -$63.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $162.00K derived: sum of 2 quarters · filed 2019-11-07 | $2.78M 10-Q · filed 2019-11-07 | $2.87M derived: sum of 4 quarters · filed 2020-03-05 | |
| 2018-06-30 | $225.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $2.85M 10-Q · filed 2019-08-07 | $2.93M derived: sum of 3 quarters · filed 2020-03-05 | $2.09M derived: sum of 4 quarters · filed 2020-03-05 | |
| 2018-03-31 | $2.62M 10-Q · filed 2019-05-08 | $2.70M derived: sum of 2 quarters · filed 2020-03-05 | $1.87M derived: sum of 3 quarters · filed 2020-03-05 | $1.81M derived: sum of 4 quarters · filed 2020-03-05 | |
| 2017-12-31 | $81.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | -$753.00K derived: sum of 2 quarters · filed 2020-03-05 | -$812.00K derived: sum of 3 quarters · filed 2020-03-05 | $329.00K 10-K · filed 2020-03-05 | |
| 2017-09-30 | -$834.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | -$893.00K derived: sum of 2 quarters · filed 2018-11-05 | $248.00K 10-Q · filed 2018-11-05 | $1.80M derived: sum of 4 quarters · filed 2019-03-07 | |
| 2017-06-30 | -$59.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $1.08M 10-Q · filed 2018-08-08 | $2.63M derived: sum of 3 quarters · filed 2019-03-07 | $2.32M derived: sum of 4 quarters · filed 2019-03-07 | |
| 2017-03-31 | $1.14M 10-Q · filed 2018-05-09 | $2.69M derived: sum of 2 quarters · filed 2019-03-07 | $2.38M derived: sum of 3 quarters · filed 2019-03-07 | $2.16M derived: sum of 4 quarters · filed 2019-03-07 | |
| 2016-12-31 | $1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $1.24M derived: sum of 2 quarters · filed 2019-03-07 | $1.02M derived: sum of 3 quarters · filed 2019-03-07 | $1.63M 10-K · filed 2019-03-07 | |
| 2016-09-30 | -$314.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$533.00K derived: sum of 2 quarters · filed 2017-11-08 | $80.00K 10-Q · filed 2017-11-08 | $566.00K derived: sum of 4 quarters · filed 2018-03-08 | |
| 2016-06-30 | -$219.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $394.00K 10-Q · filed 2017-08-10 | $880.00K derived: sum of 3 quarters · filed 2018-03-08 | $1.15M derived: sum of 4 quarters · filed 2018-03-08 | |
| 2016-03-31 | $613.00K 10-Q · filed 2017-05-09 | $1.10M derived: sum of 2 quarters · filed 2018-03-08 | $1.36M derived: sum of 3 quarters · filed 2018-03-08 | $1.47M derived: sum of 4 quarters · filed 2018-03-08 | |
| 2015-12-31 | $486.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $751.00K derived: sum of 2 quarters · filed 2018-03-08 | $861.00K derived: sum of 3 quarters · filed 2018-03-08 | $1.21M 10-K · filed 2018-03-08 | |
| 2015-09-30 | $265.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $375.00K derived: sum of 2 quarters · filed 2016-11-14 | $719.00K 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | $110.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $454.00K 10-Q · filed 2016-08-15 | |||
| 2015-03-31 | $344.00K 10-Q · filed 2016-05-16 | ||||
| 2014-12-31 | -$64.00K 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |